Renal Failure Clinical Trial
Official title:
Prospective Randomized Trial of Fistula vs. Forearm AV Graft in Patients With Poor Venous Access; Protocol #3, Version 1
The primary objective of this study is to compare two treatment strategies for establishing dialysis access in patients with unsuitable forearm veins for the standard forearm primary radio-cephalic arteriovenous fistula also known as the Brescia-Cimino fistula.
BACKGROUND AND SIGNIFICANCE:
Among patients with end stage renal disease (ESRD) who require hemodialysis, the maintenance
of an adequate vascular access is of critical importance. As the overall population in the
U.S. ages, every year a greater number of patients are being maintained on hemodialysis with
an estimated Medicare expenditure in excess of 1.25 billion dollars per year.1 The
complications related to dialysis access are a major determinant of patient outcomes,
including morbidity and mortality, and between 16-25% of hospital admissions for dialysis
patients in the U.S. are related to dialysis access complications with an estimated cost of
100 million dollars.2
For patients with ESRD requiring chronic hemodialysis, the autogenous Brescia-Cimino fistula
is the consensus best choice for the creation of an AV access site for hemodialysis. This
type of primary fistula uses the radial artery at the wrist and a suitable cephalic vein at
the level of the wrist. The fistula typically matures in 6-8 weeks when the vein and artery
are normal, and provides good flow rates with a minimal incidence of ischemia of the hand.
Infection rates are extremely low and long term patency is excellent. The disadvantage is a
low maturation rate when the vein has segments of fibrosis from previous IV sites or
venipunctures which are common in the cephalic vein at the wrist. Difficulty with fistula
maturation can lead to prolonged time with a tunneled dialysis catheter (TDC) while the
patient undergoes a variety of procedures to correct the fistula and allow it to mature. Up
to 40% of forearm primary Brescia-Cimino fistulas either fail to mature or occlude prior to
use, and the incidence of failure of forearm fistulas is significantly higher in women
compared to men. Infection rates with tunneled dialysis catheters are roughly 10 times that
of fistulas or grafts; therefore, months or even years with TDCs, while fistulas mature, can
have consequences. Infections are estimated to account for 14% of deaths in ESRD patients.3
In the absence of a suitable cephalic vein at the wrist or in case of poor maturation, the
two main options exist. They are both acceptable in clinical practice and are chosen based
on the particular clinical scenario and, to some extent, surgeon preference. The options
include:
1. ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal
forearm to the radial or brachial artery and to an antecubital vein. The advantages
include a quick maturation of 2-3 weeks, excellent flow rates and high technical
success rates. Although secondary patency rates approach 80% at one year
postoperatively, disadvantages include a more involved surgical procedure, a lower
primary patency than a well functioning AV fistula, and higher revision and infection
rates.4, 5
2. Performing other autogenous AV fistulas which include various options such as
brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of
other strategies to maintain a primary access. The advantage would be to maintain an
autogenous all venous access with less risk of infection and thrombosis. Some of these
procedures, however, may involve an extensive dissection, a longer time for maturation,
and the resulting fistula can be more difficult to use even if functioning well.
Several procedures are also performed on occasion to aid in maturation before an AV
fistula is actually available for access. In addition, a "steal" phenomenon is more
common with proximal fistulas as the flow rates can be excessively high with low
central resistance in the larger veins, leading to a decrease in blood flow to the
hand. All of these factors often translate into prolonged central venous catheter
placement (TDC) for dialysis, which has been associated with a high incidence of
infection and central vein stenosis, or thrombosis.6
Because of the superior patency of primary fistulas, the Kidney Disease Outcomes Quality
Initiative (K/DOQI) and the Fistula First initiative have articulated the advantages of
fistulas vs. ePTFE bridge grafts for long-term dialysis access and recommended that at least
50% of patients in any region be on dialysis through a primary fistula.7 In addition, in
2006 K/DOQI set a target of 66% for prevalent fistulas by 2009.8 Many surgeons have also
adopted a 100% autogenous policy because of these recommendations without a critical
assessment of the potential downside of that policy.9 Others continue to use ePTFE
preferentially when a cephalic vein is not available.
Although there is no doubt that in suitable patients a primary fistula is better than a
prosthetic graft, there are no data to guide the best treatment strategy in the absence of a
suitable forearm cephalic vein. Although K/DOQI encourages creation of primary fistulas, the
multiple procedures required for fistula maturation and prolonged time with tunneled
dialysis catheters, their complications may outweigh the complications of ePTFE grafts.10
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02763410 -
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
|
||
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Suspended |
NCT04589065 -
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
|
N/A | |
Completed |
NCT03806998 -
Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
|
Phase 3 | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
Completed |
NCT02116270 -
Accelerated Immunosenescence and Chronic Kidney Disease
|
N/A | |
Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
Completed |
NCT01388270 -
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
|
Phase 4 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01187953 -
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacroâ„¢ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
|
Phase 3 | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT01008631 -
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers
|
N/A | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Recruiting |
NCT00470769 -
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR
|
N/A | |
Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 |